Table 1 Recommended timing of PET... | American Society of Hematology

Table 1

Recommended timing of PET (PET/CT) scans in lymphoma clinical trials

Histology	Before treatment	Middle of treatment	Response assessment	Surveillance after tx
Routinely FDG avid
DLBCL	Yes*	Clinical trial	Yes	No
HL	Yes*	Clinical trial	Yes	No
Follicular NHL	No†	Clinical trial	No†	No
MCL	No†	Clinical trial	No†	No
Variably FDG avid
Other aggressive NHLs	No†	Clinical trial	No †‡	No
Other indolent NHLs	No†	Clinical trial	No †‡	No

Histology	Before treatment	Middle of treatment	Response assessment	Surveillance after tx
Routinely FDG avid
DLBCL	Yes*	Clinical trial	Yes	No
HL	Yes*	Clinical trial	Yes	No
Follicular NHL	No†	Clinical trial	No†	No
MCL	No†	Clinical trial	No†	No
Variably FDG avid
Other aggressive NHLs	No†	Clinical trial	No †‡	No
Other indolent NHLs	No†	Clinical trial	No †‡	No

tx indicates transplantation; DLBCL, diffuse large B-cell lymphoma; and MCL, mantle cell lymphoma.

Recommended but not required before treatment.

Recommended only if ORR/CR is a primary study end point.

Recommended only if PET is positive before treatment.